

Kirk R Schultz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2395163/kirk-r-schultz-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

179
papers

9,383
citations

43
h-index

95
g-index

192
ext. papers

11,120
ext. citations

3.6
avg, IF

5.21
L-index

#	Paper	IF	Citations
179	Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia 2022 , 405-430		
178	Urine Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 to Detect Pediatric Cisplatin-Associated Acute Kidney Injury.. <i>Kidney360</i> , 2022 , 3, 37-50	1.8	0
177	Is It Possible to Separate the Graft-Versus-Leukemia (GVL) Effect Against B Cell Acute Lymphoblastic Leukemia From Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplant?. <i>Frontiers in Pediatrics</i> , 2022 , 10, 796994	3.4	
176	236 Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant. <i>Journal of Clinical and Translational Science</i> , 2022 , 6, 37-38	0.4	
175	What Is the Role of HSCT in Philadelphia-Chromosome-Positive and Philadelphia-Chromosome-Like ALL in the Tyrosine Kinase Inhibitor Era?. <i>Frontiers in Pediatrics</i> , 2021 , 9, 807002	3.4	
174	Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2021 , 138, 3880-3880	2.2	1
173	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 452-466		7
172	Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2193-2201	1.9	1
171	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2108-2117	4.4	1
170	Successful rescue transplant for children with primary graft failure using early intervention with a single day preparative regimen and related haploidentical donor. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2031-2033	4.4	0
169	Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1865-1877	2.2	18
168	Has Eltrombopag eliminated the need to use allogeneic HSCT in first line treatment of pediatric aplastic anemia?. <i>Pediatric Hematology and Oncology</i> , 2021 , 38, 417-419	1.7	
167	Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers. <i>Journal of Clinical Immunology</i> , 2021 , 41, 38-50	5.7	5
166	A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2021 , 137, 983-993	2.2	5
165	Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e28574	3	2
164	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 545-557		15
163	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 632-641		6

162	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 729-737		5
161	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 817-835		5
160	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2062-2076	2.2	19
159	Epidemiologic Characteristics of Acute Kidney Injury During Cisplatin Infusions in Children Treated for Cancer. <i>JAMA Network Open</i> , 2020 , 3, e203639	10.4	10
158	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Hematologica</i> , 2020 , 105, 1329-1339	6.6	9
157	Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Haematology</i> , 2020 , 7, e100-111	14.6	32
156	Experience with ponatinib in paediatric patients with leukaemia. <i>British Journal of Haematology</i> , 2020 , 189, 363-368	4.5	11
155	Regional differences in access to hematopoietic stem cell transplantation among pediatric patients with acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28263	3	0
154	Naïve Helper T-Cell and Regulatory T- and NK-Cell Subsets Are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTc 1202 Study. <i>Blood</i> , 2020 , 136, 11-12	2.2	0
153	Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2020 , Online ahead of print,	6.6	3
152	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 472-479	4.7	7
151	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 553-561	4.7	5
150	Anti-Thymocyte Globulin Prophylaxis Induces a Decrease in Naive Th Cells to Inhibit the Onset of Chronic Graft-versus-Host Disease: Results from the Canadian Bone Marrow Transplant Group (CBMTG) 0801 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 438-444	4.7	1
149	How we approach Philadelphia chromosome-positive acute lymphoblastic leukemia in children and young adults. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28543	3	6
148	"Age Related Differences in the Biology of Chronic Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation". <i>Frontiers in Immunology</i> , 2020 , 11, 571884	8.4	3
147	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3282-3293	2.2	51
146	Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTc 1202 studies. <i>Blood</i> , 2020 , 135, 1287-1298	2.2	18
145	The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TAcl T2009-008 phase I study. <i>Pediatric Hematology and Oncology</i> , 2019 , 36, 468-481	1.7	6

144	Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. <i>Pediatric Blood and Cancer</i> , 2019 , 66, e27827	3	22
143	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1875-1883	4.7	7
142	Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. <i>Blood</i> , 2019 , 134, 304-316	2.2	31
141	Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2019 , 37, 780-789	2.2	33
140	Access to Hematopoietic Stem Cell Transplantation among Pediatric Patients with Acute Lymphoblastic Leukemia: A Population-Based Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1172-1178	4.7	3
139	Too stressed for tests? Challenges of diagnosing psychological distress in pediatric cancer patients and survivors. <i>Pediatric Hematology and Oncology</i> , 2019 , 36, 123-124	1.7	
138	Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial. <i>Blood</i> , 2019 , 134, 875-875	2.2	
137	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019 , 3, 1441-1449	7.8	7
136	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019 , 3, 1826-1836	7.8	50
135	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019 , 3, 3123-3131	7.8	18
134	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. <i>Blood Advances</i> , 2019 , 3, 3393-3405	7.8	47
133	Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 451-458	4.7	10
132	The case for plerixafor to replace filgrastim as the optimal agent to mobilize peripheral blood donors for allogeneic hematopoietic cell transplantation. <i>Experimental Hematology</i> , 2019 , 70, 1-9	3.1	8
131	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 270-278	4.7	14
130	Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 321-327	4.7	6
129	Prolonged granulocyte colony stimulating factor use in glycogen storage disease type 1b associated with acute myeloid leukemia and with shortened telomere length. <i>Pediatric Hematology and Oncology</i> , 2018 , 35, 45-51	1.7	17
128	Biomarkers in chronic graft-versus-host disease: quo vadis?. <i>Bone Marrow Transplantation</i> , 2018 , 53, 832-837	4.7	36
127	Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. <i>Leukemia</i> , 2018 , 32, 2316-2325	10.7	60

126	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1928-1935	4.7	1
125	Higher levels of free plasma mitochondrial DNA are associated with the onset of chronic GvHD. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1263-1269	4.4	5
124	Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 141, 322-328.e10	11.5	53
123	Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. <i>Blood</i> , 2018 , 132, 1438-1451	2.2	55
122	EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1401-1415	4.4	120
121	Provincial Disparities in Access to Allogeneic Transplant in Canada. <i>Blood</i> , 2018 , 132, 4742-4742	2.2	
120	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434. <i>Blood</i> , 2018 , 132, 659-659	2.2	
119	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 521-528	4.7	19
118	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2306-2314	2.2	119
117	Tumor Variant Identification That Accounts for the Unique Molecular Landscape of Pediatric Malignancies. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky079	4.6	4
116	Relationship between cyclosporine area-under-the curve and acute graft versus host disease in pediatric patients undergoing hematopoietic stem cell transplant: A prospective, multicenter study. <i>Pediatric Hematology and Oncology</i> , 2018 , 35, 288-296	1.7	3
115	Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e27431	3	10
114	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. <i>Blood Advances</i> , 2018 , 2, 1022-1031	7.8	8
113	Plerixafor effectively mobilizes CD56 NK cells in blood, providing an allograft predicted to protect against GVHD. <i>Blood</i> , 2018 , 131, 2863-2866	2.2	9
112	Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2040-2046	4.7	18
111	Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2017 , 4, 2054358117690338	2.3	11
110	Improved survival after acute graft--host disease diagnosis in the modern era. <i>Haematologica</i> , 2017 , 102, 958-966	6.6	50
109	Y-box-binding protein 1 contributes to IL-7-mediated survival signaling in B-cell precursor acute lymphoblastic leukemia. <i>Oncology Letters</i> , 2017 , 13, 497-505	2.6	4

108	CD56 natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft–host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results. <i>Haematologica</i> , 2017 , 102, 1936-1946	6.6	13
107	Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1714-1721	4.7	17
106	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 870-881	4.7	26
105	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 211-234	4.7	206
104	CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). <i>Blood</i> , 2017 , 130, 98-98	2.2	17
103	Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. <i>Blood</i> , 2016 , 127, 3082-91	2.2	57
102	Successful clinical treatment and functional immunological normalization of human MALT1 deficiency following hematopoietic stem cell transplantation. <i>Clinical Immunology</i> , 2016 , 168, 1-5	9	25
101	Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 932-40	4.7	30
100	Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. <i>Lancet Oncology</i> , 2016 , 17, 164-173	21.7	199
99	Umbilical Cord Blood (UCB) Transplantation in Children with Acute Leukemia: Impact of Conditioning Regimen on Transplant Outcomes. <i>Blood</i> , 2016 , 128, 1231-1231	2.2	1
98	Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1410-1415	4.7	16
97	Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. <i>Blood</i> , 2016 , 127, 392-9	2.2	101
96	Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2016 , 101, 1267-1274	6.6	13
95	Quantitation of Human Cells that Produce Neutrophils and Platelets in Vivo Obtained from Normal Donors Treated with Granulocyte Colony-Stimulating Factor and/or Plerixafor. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1945-1952	4.7	3
94	Functional hyposplenism after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015 , 50, 1343-7	4.4	6
93	Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1029-36	4.7	49
92	Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 984-99	4.7	196
91	Hematopoietic Stem Cell Transplantation for X-Linked Thrombocytopenia With Mutations in the WAS gene. <i>Journal of Clinical Immunology</i> , 2015 , 35, 15-21	5.7	20

90	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1167-87	4.7	128
89	Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1790-5	4.7	6
88	Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 266-74	4.7	214
87	TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 67-73	4.7	48
86	Is any donor too old?. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2-3	4.7	2
85	Hematopoietic cell transplantation and cellular therapeutics in the treatment of childhood malignancies. <i>Pediatric Clinics of North America</i> , 2015 , 62, 257-73	3.6	7
84	Will post-transplantation cell therapies for pediatric patients become standard of care?. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 402-11	4.7	8
83	In Vivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2173-2179	4.7	21
82	Heterodimer-specific TLR2 stimulation results in divergent functional outcomes in B-cell precursor acute lymphoblastic leukemia. <i>European Journal of Immunology</i> , 2015 , 45, 1980-90	6.1	10
81	Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?. <i>Bone Marrow Transplantation</i> , 2015 , 50, 1173-9	4.4	46
80	IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. <i>Blood</i> , 2015 , 125, 3501-8	2.2	135
79	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 780-92	4.7	87
78	NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 589-603	4.7	165
77	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2015 , 126, 807-807	2.2	4
76	Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031. <i>Leukemia</i> , 2014 , 28, 964-7	10.7	21
75	Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. <i>Leukemia</i> , 2014 , 28, 1467-71	10.7	298
74	Combined immunodeficiency associated with homozygous MALT1 mutations. <i>Journal of Allergy and Clinical Immunology</i> , 2014 , 133, 1458-62, 1462.e1-7	11.5	91
73	One-unit versus two-unit cord-blood transplantation for hematologic cancers. <i>New England Journal of Medicine</i> , 2014 , 371, 1685-94	59.2	214

72	New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL. <i>Bone Marrow Transplantation</i> , 2014 , 49, 1259-65	4.4	17
71	Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2014 , 124, 2596-606	2.2	184
70	The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. <i>Blood</i> , 2014 , 123, 2017-25	2.2	93
69	Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. <i>Blood</i> , 2014 , 123, 1615-20	2.2	46
68	Circulating Angiogenic Factors As Biomarkers of Acute Gvhd Onset and Response to Therapy: Repair and Regeneration Versus Endothelial Damage and Inflammation. <i>Blood</i> , 2014 , 124, 2489-2489	2.2	1
67	Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial. <i>Blood</i> , 2014 , 124, 38-38	2.2	14
66	Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL). <i>Blood</i> , 2014 , 124, 795-795	2.2	16
65	Prior Granulocyte Colony-Stimulating Factor Treatment Enhances the Immediate and Transient Output of Primitive Hematopoietic Cells in the Blood of Normal Adult Human Donors Treated with Plerixafor. <i>Blood</i> , 2014 , 124, 5787-5787	2.2	
64	Severe combined immunodeficiency (SCID) in Canadian children: a national surveillance study. <i>Journal of Clinical Immunology</i> , 2013 , 33, 1310-6	5.7	24
63	STAT3 mutations and persistence of autoimmunity. <i>Blood</i> , 2013 , 122, 2295-6	2.2	5
62	Multicenter Investigation Of Unrelated Donor Hematopoietic Cell Transplantation (HCT) For Thalassemia Major After a Reduced Intensity Conditioning Regimen (URTH Trial). <i>Blood</i> , 2013 , 122, 543-543	2.2	9
61	A Canadian Blood and Marrow Transplant Group (CBMTG) Randomised Trial Comparing G-CSF Mobilized Peripheral Blood Versus G-CSF Stimulated Bone Marrow In Recipients Of Sibling Allografts For Hematologic Malignancies. <i>Blood</i> , 2013 , 122, 709-709	2.2	3
60	Striking Predictive Power For Relapse and Decreased Survival Associated With Detectable Minimal Residual Disease by IGH VDJ Deep Sequencing Of Bone Marrow Pre- and Post-Allogeneic Transplant In Children With B-Lineage ALL: A Subanalysis Of The COG ASCT0431/PBMTG ONC051 Study. <i>Blood</i> , 2013 , 122, 919-919	2.2	3
59	Heterodimer-Specific Stimulation Of Toll-Like Receptor 2 Induces Divergent Downstream Effects In Primary Samples Of Precursor B Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013 , 122, 3918-3918	2.2	1
58	Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 84-91	4.7	44
57	Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622. <i>Blood</i> , 2012 , 120, 137-137	2.2	4
56	No Survival Advantage After Double Umbilical Cord Blood (UCB) Compared to Single UCB Transplant in Children with Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial. <i>Blood</i> , 2012 , 120, 359-359	2.2	9
55	The Relationship of Acute Gvhd and Pre- and Post-Transplant Flow-MRD to the Incidence and Timing of Relapse in Children Undergoing Allogeneic Transplantation for High Risk ALL: Defining a Target Population and Window for Immunological Intervention to Prevent Relapse. <i>Blood</i> , 2012 , 120, 470-470	2.2	3

54	Amino Acid Substitution At Peptide-Binding Pockets of HLA Class I Molecules Adversely Impacts Hematopoietic Cell Transplantation Outcomes. <i>Blood</i> , 2012 , 120, 467-467	2.2	
53	Functional Hyposplenism in Pediatric Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2012 , 120, 4493-4493	2.2	
52	YB-1 Is Activated by IL-7 and Is Overexpressed in Pediatric Pre-B Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012 , 120, 1468-1468	2.2	
51	Higher Proportions of IFN γ -Producing T Cells, CD56bright NK Cells and Immature B Cells in the Lymphocytes of G-CSF Stimulated Donor Grafts Are Associated with Less Chronic Gvhd After HSCT: Results From the Canadian BMT Group 0601 Randomized, Phase III Trial. <i>Blood</i> , 2012 , 120, 1944-1944	2.2	
50	Controversies in the treatment of CML in children and adolescents: TKIs versus BMT?. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, S115-22	4.7	30
49	Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1804-13	4.7	29
48	Biomarkers in chronic graft-versus-host disease. <i>Expert Review of Hematology</i> , 2011 , 4, 329-42	2.8	17
47	Immunosuppressive therapy without hematopoietic growth factor exposure in pediatric acquired aplastic anemia. <i>Pediatric Hematology and Oncology</i> , 2011 , 28, 469-78	1.7	13
46	A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431. <i>Blood</i> , 2011 , 118, 837-837	2.2	1
45	Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031. <i>Bone Marrow Transplantation</i> , 2010 , 45, 1653-7	4.4	4
44	Chronic graft-versus-host disease (GVHD) in children. <i>Pediatric Clinics of North America</i> , 2010 , 57, 297-323.6		87
43	Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options. <i>Expert Review of Hematology</i> , 2010 , 3, 731-42	2.8	11
42	Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. <i>Blood</i> , 2010 , 116, 4007-15	2.2	94
41	Therapeutic Potential for Toll-Like Receptor 2 Agonists In Pediatric Acute Lymphoblastic Leukemia (pre-B ALL): Induction of Apoptosis and Anti-ALL Immunogenicity. <i>Blood</i> , 2010 , 116, 870-870	2.2	
40	Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5175-81 ²		54 ⁰
39	Acute T-Cell Leukemias Remain Dependent On Notch Signaling Despite PTEN and INK4A/ARF Loss.. <i>Blood</i> , 2009 , 114, 8-8	2.2	3
38	Secondary Chromosomal Abnormalities Appear to Be Less Prognostic for Children with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with Intensified Imatinib and Chemotherapy: Results of the Children's Oncology Group (COG) Study AALL0031.. <i>Blood</i> , 2009 , 114, 2606-2606	2.2	
37	Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group.. <i>Blood</i> , 2009 , 114, 2634-2634	2.2	

36	The Presence of HLA DR15 Antigen in Patients with Severe Aplastic Anemia Does Not Impact Engraftment and Survival After HLA-Identical Sibling Transplantation.. <i>Blood</i> , 2009 , 114, 2280-2280	2.2	
35	Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. <i>Blood</i> , 2008 , 111, 3276-85	2.2	117
34	Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Children's Oncology Group (COG) Study AALL0031.. <i>Blood</i> , 2008 , 112, 911-911	2.2	1
33	Impact of Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplant for Children with AML beyond the First Complete Remission: Total Body Irradiation Versus Busulfan- a Pediatric Blood and Marrow Transplant Consortium (PBMTC) Study. <i>Blood</i> , 2008 , 112, 3006-3006	2.2	
32	Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 218-27	4.7	56
31	Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 386-97	4.7	71
30	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). <i>Blood</i> , 2007 , 109, 926-35	2.2	338
29	Chronic Graft-Versus-Host Disease after Tacrolimus Versus Cyclosporine for Graft-Versus-Host Disease Prophylaxis in Pediatric Patients Undergoing Matched Unrelated Donor Hematopoietic Stem Cell Transplantation. A Pediatric Blood and Marrow Transplant Consortium Study... <i>Blood</i> , 2007 , 110, 1001-1001	2.2	
28	Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 31-47	4.7	357
27	Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 126-37	4.7	127
26	HLA-DM expression is elevated in ETV6-AML1 translocation-positive pediatric acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2006 , 30, 487-9	2.7	9
25	In Vivo Control of Acute Lymphoblastic Leukemia by Immunostimulatory CpG Oligonucleotides.. <i>Blood</i> , 2006 , 108, 1868-1868	2.2	1
24	National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 945-56	4.7	2749
23	Differential effects of granulocyte colony-stimulating factor on marrow- and blood-derived hematopoietic and immune cell populations in healthy human donors. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 624-34	4.7	42
22	Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).. <i>Blood</i> , 2004 , 104, 519-519	2.2	2
21	Detection of T-Cells Specific for Leukemia-Associated Antigens in Pediatric Patients with Acute Lymphoblastic Leukemia in First Complete Remission.. <i>Blood</i> , 2004 , 104, 526-526	2.2	
20	An Exaggerated B Cell CpG Response in Human Chronic Graft-versus-Host Disease: A Potential Mechanism and Biomarker for Diagnosis of Chronic GVHD.. <i>Blood</i> , 2004 , 104, 4966-4966	2.2	1
19	A population-based study of pediatric anaplastic large cell lymphoma. <i>Cancer</i> , 2002 , 94, 1830-5	6.4	26

18	ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype. <i>British Journal of Haematology</i> , 2002 , 116, 266-272	4.5	24
17	Chloroquine prevention of murine MHC-disparate acute graft-versus-host disease correlates with inhibition of splenic response to CpG oligodeoxynucleotides and alterations in T-cell cytokine production. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 648-55	4.7	18
16	Absence of t(12;15) associated ETV6-NTRK3 fusion transcripts in pediatric acute leukemias. <i>Medical and Pediatric Oncology</i> , 2001 , 37, 415-6		10
15	Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma. <i>Medical and Pediatric Oncology</i> , 2000 , 35, 41-6		75
14	Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2000 , 26, 545-51	4.4	27
13	A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. <i>British Journal of Haematology</i> , 1999 , 106, 1027-32	4.5	90
12	Misleading leads: Bone pain caused by isolated paraspinal extramedullary relapse of childhood acute lymphoblastic leukemia. <i>Medical and Pediatric Oncology</i> , 1999 , 33, 113-5		5
11	The pharmacokinetics of oral cyclosporin A (Neoral) during the first month after bone marrow transplantation. <i>Transplantation Proceedings</i> , 1998 , 30, 1668-70	1.1	10
10	The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease. <i>Leukemia and Lymphoma</i> , 1997 , 24, 201-10	1.9	53
9	Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia. <i>Medical and Pediatric Oncology</i> , 1997 , 29, 16-22		27
8	Treatment of familial erythrophagocytic lymphohistiocytosis with cyclosporine A. <i>Journal of Pediatrics</i> , 1997 , 130, 467-70	3.6	13
7	Synergy between lysosomotropic amines and cyclosporin A on human T cell responses to an exogenous protein antigen, tetanus toxoid. <i>Bone Marrow Transplantation</i> , 1996 , 18, 625-31	4.4	11
6	Obstructive lung disease in children after allogeneic bone marrow transplantation: evaluation with high-resolution CT. <i>American Journal of Roentgenology</i> , 1995 , 164, 693-6	5.4	43
5	Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease. <i>Blood</i> , 1995 , 86, 4344-52	2.2	7
4	Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 1995 , 16, 289-95	4.4	82
3	Obstructive lung disease in children after allogeneic bone marrow transplantation. <i>Blood</i> , 1994 , 84, 3212-20		16
2	An increased relative frequency of retinoblastoma at a rural regional referral hospital in Miraj, Maharashtra, India. <i>Cancer</i> , 1993 , 72, 282-6	6.4	40
1	Pathophysiology of Chronic Graft versus Host Disease17-30		6

